twoXAR is a pharmaceutical company that has built a development portfolio targeting more than 18 different diseases. twoXAR’s unique approach to drug discovery combines steps from the traditional multi-step approach to R&D that severely limits the pace of drug discovery. This novel method – coupled with the company’s proprietary AI-driven platform – enables twoXAR to select a disease and initiate in vivo testing in months, instead of years.



    Our vision is to become the global leader in drug discovery and development by developing new medicines to benefit a billion patients.



    The convergence of big data, cloud computing, and artificial intelligence has allowed twoXAR to build a drug discovery platform that is orders of magnitude faster, cheaper, and more accurate than traditional approaches.


    twoXAR leverages its AI technology internally to build its own pipeline of therapeutic candidates across diseases as well as collaborate with biotechnology and pharmaceutical companies to jointly discover and develop novel drug candidates.​

  • The Applications of AI in Drug Discovery

    twoXAR Corporate Seminar

    July 19, 2019

    Latest Updates

    Ophthalmic Drugs

    London, UK

    November 19-20, 2019

    twoXAR VP Discovery, Aaron Daugherty, discusses the applications of AI in Drug Discovery.

    FT Global Pharmaceutical and Biotechnology Conference​

    London, UK

    November 11-12, 2019

    twoXAR CEO, Andrew A. Radin, joins a panel discussion on 'Digital R&D: AI - The Reckoning?'